doi: 10.1016/S0140-6736(98)09344-1 PubMed Abstract | CrossRef Full Text | Google Scholar Anderson, C., Beare, M., Buckley, H
GLP-1 receptor agonists or GLP-1 analogues are an attractive and recommended therapeutic option for type 2 diabetes because of their demonstrated effects on glycaemic control and weight loss, and positive impact on cardiovascular outcomes [6, 17,18,19]
A case of morbilliform drug eruption to dulaglutide
Subjects were matched by body mass and then randomly assigned to one of three study groups, with one group receiving 1.5 grams per day of GPLC, one group receiving 3.0 grams GPLC per day, and the final group receiving a daily dosage of 4.5 grams of GPLC